Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.

Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH.

Br J Dermatol. 2013 Aug;169(2):306-13. doi: 10.1111/bjd.12341.

PMID:
23550925
2.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Adalimumab for the treatment of psoriasis.

Turner D, Picot J, Cooper K, Loveman E.

Health Technol Assess. 2009 Sep;13 Suppl 2:49-54. doi: 10.3310/hta13suppl2/07. Review.

5.

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

Langley RG.

J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:21-9. doi: 10.1111/j.1468-3083.2011.04412.x. Review.

PMID:
22356632
6.

[Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].

Levy-Roy A, Porcher R, de Fonclare AL, Morel P, Dupuy A.

Ann Dermatol Venereol. 2009 Apr;136(4):315-22. doi: 10.1016/j.annder.2008.11.016. Epub 2009 Jan 30. Review. French.

PMID:
19361697
7.

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.

Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM.

Br J Dermatol. 2010 Jun;162(6):1349-58. doi: 10.1111/j.1365-2133.2010.09707.x. Epub 2010 Apr 14. Review.

PMID:
20394634
8.

Anti-TNF agents for the treatment of psoriasis.

Kircik LH, Del Rosso JQ.

J Drugs Dermatol. 2009 Jun;8(6):546-59. Review.

PMID:
19537380
9.

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.

Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A.

Dermatology. 2009;219(3):209-18. doi: 10.1159/000233234. Epub 2009 Aug 5. Review.

PMID:
19657180
10.

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.

Mossner R, Reich K.

Curr Probl Dermatol. 2009;38:107-36. doi: 10.1159/000232307. Epub 2009 Jul 28. Review.

PMID:
19710553
11.

Antidrug antibodies in psoriasis: a systematic review.

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654. Review.

PMID:
24117166
12.

Immunogenicity of anti-TNF╬▒ therapy in psoriasis: a clinical issue?

De Simone C, Amerio P, Amoruso G, Bardazzi F, Campanati A, Conti A, Gisondi P, Gualdi G, Guarneri C, Leoni L, Loconsole F, Mazzotta A, Musumeci ML, Piaserico S, Potenza C, Prestinari F.

Expert Opin Biol Ther. 2013 Dec;13(12):1673-82. doi: 10.1517/14712598.2013.848194. Epub 2013 Oct 10. Review.

PMID:
24107126
13.

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.

Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR.

J Am Acad Dermatol. 2008 Jan;58(1):125-35. Epub 2007 Nov 8. Review.

PMID:
17996329
14.

Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16. Review.

PMID:
24738910
15.

Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21. Review.

PMID:
25288183
16.

Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review.

Puig L, Barco D, Vilarrasa E, Alomar A.

Dermatology. 2010;220(2):154-8. doi: 10.1159/000277415. Epub 2010 Jan 26. Review.

PMID:
20110631
17.

Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies.

Papp K, Okun M, Vender R.

J Cutan Med Surg. 2009 Sep-Oct;13 Suppl 2:S58-66. Review.

PMID:
19799828
18.

Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.

Gilbert KE, Manalo IF, Wu JJ.

J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012. Review. No abstract available.

PMID:
26183982
19.

Biologic fatigue in psoriasis.

Levin EC, Gupta R, Brown G, Malakouti M, Koo J.

J Dermatolog Treat. 2014 Feb;25(1):78-82. doi: 10.3109/09546634.2013.826341. Epub 2013 Aug 27. Review.

PMID:
23875537
20.

Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.

Hsu L, Armstrong AW.

Expert Rev Clin Immunol. 2013 Oct;9(10):949-58. doi: 10.1586/1744666X.2013.836060. Review.

PMID:
24128157

Supplemental Content

Support Center